GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marker Therapeutics Inc (FRA:GX1) » Definitions » General and Admin. Expense

Marker Therapeutics (FRA:GX1) General and Admin. Expense : €4.08 Mil (TTM As of Mar. 2025)


View and export this data going back to . Start your Free Trial

What is Marker Therapeutics General and Admin. Expense?

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company. Marker Therapeutics's General and Admin. Expense for the three months ended in Mar. 2025 was €1.27 Mil. Its General and Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2025 was €4.08 Mil.

Marker Therapeutics General and Admin. Expense Historical Data

The historical data trend for Marker Therapeutics's General and Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Marker Therapeutics General and Admin. Expense Chart

Marker Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
General and Admin. Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.61 11.44 10.70 6.86 4.05

Marker Therapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
General and Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.12 1.06 0.77 0.98 1.27

Marker Therapeutics General and Admin. Expense Calculation

General and Admin. Expense is the aggregate total of general managing and administering expenses for the company.

General and Admin. Expense for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €4.08 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Marker Therapeutics General and Admin. Expense Related Terms

Thank you for viewing the detailed overview of Marker Therapeutics's General and Admin. Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Marker Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Marker Therapeutics Inc (FRA:GX1) » Definitions » General and Admin. Expense
Comparable Companies
LEXX PSTV SABS CTXR COCP CING CARM RVPH LPCN HSTC VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:UCB XBRU:ARGX ONC XKRX:068270 BNTX
Traded in Other Exchanges
MRKR:USA
Address
2450 Holcombe Boulevard, Suite e BCM-A, MS: BCM251, Houston, TX, USA, 77021
Website
https://www.markertherapeutics.com
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.

Marker Therapeutics Headlines

No Headlines